دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Starvation as a weapon of war must stop
doi : 10.1016/S0140-6736(24)00684-6
Volume 403, Issue 10434, 6–12 April 2024, Page 1309
Immunotherapy plus chemoradiotherapy in cervical cancer management
Krishnansu S Tewari a, Bradley J Monk b
doi : 10.1016/S0140-6736(24)00468-9
Volume 403, Issue 10434, 6–12 April 2024, Pages 1310-1311
Integrating management of treatment toxicity on patient quality of life in real-world cancer clinics
Susanne Oksbjerg Dalton a b c d, Christoffer Johansen c d
doi : 10.1016/S0140-6736(24)00303-9
Volume 403, Issue 10434, 6–12 April 2024, Pages 1312-1313
Closing the gap in paediatric HIV infections: how available tools and technology can accelerate progress towards ending AIDS by 2030
Wilbroad Mutale a b, Michael E Herce c d
doi : 10.1016/S0140-6736(24)00366-0
Volume 403, Issue 10434, 6–12 April 2024, Pages 1313-1315
Revitalising the right to health is essential to securing better health for all
Volker Türk a
doi : 10.1016/S0140-6736(24)00582-8
Volume 403, Issue 10434, 6–12 April 2024, Pages 1315-1318
US abortion bans should not pre-empt the duty to provide life-saving abortion care to pregnant patients in medical emergencies
Michele Heisler a, Nia Mitchell b, Whitney Arey c, Michelle Erenberg d, Karla Torres e, Payal K Shah a
doi : 10.1016/S0140-6736(24)00551-8
Volume 403, Issue 10434, 6–12 April 2024, Pages 1318-1321
Retraction and republication—Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials
doi : 10.1016/S0140-6736(24)00318-0
Volume 403, Issue 10434, 6–12 April 2024, Page 1321
Offline: The death of civilian immunity
Richard Horton
doi : 10.1016/S0140-6736(24)00679-2
Volume 403, Issue 10434, 6–12 April 2024, Page 1322
Anti-LGBTQ+ laws in Africa harming health and research
Gilbert Nakweya
doi : 10.1016/S0140-6736(24)00681-0
Volume 403, Issue 10434, 6–12 April 2024, Pages 1323-1324
Biosafety regulations are not yet fit for purpose
Talha Burki
doi : 10.1016/S0140-6736(24)00682-2
Volume 403, Issue 10434, 6–12 April 2024, Pages 1325-1326
Allan Maleche: legal advocate for health justice and human rights
Aarathi Prasad
doi : 10.1016/S0140-6736(24)00643-3
Volume 403, Issue 10434, 6–12 April 2024, Page 1327
Catharsis and healing in An Enemy of the People
Miriam Lewis Sabin
doi : 10.1016/S0140-6736(24)00630-5
Volume 403, Issue 10434, 6–12 April 2024, Pages 1328-1329
In praise of serendipity
Roger Kneebone, Giulia Frezza
doi : 10.1016/S0140-6736(24)00644-5
Volume 403, Issue 10434, 6–12 April 2024, Pages 1330-1331
Roger Charles Louis Guillemin
Geoff Watts
doi : 10.1016/S0140-6736(24)00645-7
Volume 403, Issue 10434, 6–12 April 2024, Page 1332
Unwelcome changes to the Specialised Foundation Programme recruitment
Jonathan Barratt a, Debbie Sharp b, Waljit S Dhillo d, Christopher Pugh c
doi : 10.1016/S0140-6736(24)00418-5
Volume 403, Issue 10434, 6–12 April 2024, Page 1333
Governance provisions in the WHO Pandemic Agreement draft
Nina Schwalbe a b c, Elliot Hannon a, Lynda Gilby a, Susanna Lehtimaki a
doi : 10.1016/S0140-6736(24)00585-3
Volume 403, Issue 10434, 6–12 April 2024, Pages 1333-1334
WHO should embrace tobacco harm reduction to save lives
Derek Yach
doi : 10.1016/S0140-6736(24)00245-9
Volume 403, Issue 10434, 6–12 April 2024, Pages 1334-1335
WHO–Lancet Global Series on health and the arts
Stephen Clift a, Arne Bathke b, Helena Daffern d, Christina Davies c, Katarzyna Grebosz-Haring b, Mette Kaasgaard e, J Matt McCrary f, George Musgrave g, Leonhard Thun-Hohenstein h
doi : 10.1016/S0140-6736(24)00246-0
Volume 403, Issue 10434, 6–12 April 2024, Page 1335
The combination of systemic corticosteroids and inhaled adrenaline for bronchiolitis
Ben Gelbart a, Frank Shann b
doi : 10.1016/S0140-6736(23)01224-2
Volume 403, Issue 10434, 6–12 April 2024, Page 1335
Post-COVID-19 condition symptoms 6–12 months after hospitalisation in Wuhan
Arne Søraas a, Sonja H Brunvoll a, Anders B Nygaard a, John Arne Dahl a, Giske Ursin b
doi : 10.1016/S0140-6736(24)00414-8
Volume 403, Issue 10434, 6–12 April 2024, Page 1336
Post-COVID-19 condition symptoms 6–12 months after hospitalisation in Wuhan – Authors' reply
Xiaoying Gu a, Lixue Huang c, Hui Zhang b d, Bin Cao b d e
doi : 10.1016/S0140-6736(24)00415-X
Volume 403, Issue 10434, 6–12 April 2024, Pages 1336-1337
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial
Natalie McEvoy a, Jessica Lowry b c, Aidan O'Dowd a, Gerard F Curley a, Fidelma Fitzpatrick b c
doi : 10.1016/S0140-6736(23)02880-5
Volume 403, Issue 10434, 6–12 April 2024, Page 1337
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial
Zia Hashim a, Alok Nath a, Naresh Kumar Tripathy b
doi : 10.1016/S0140-6736(23)02882-9
Volume 403, Issue 10434, 6–12 April 2024, Pages 1337-1338
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial
Nin-Chieh Hsu a b, Yasuharu Tokuda c
doi : 10.1016/S0140-6736(23)02883-0
Volume 403, Issue 10434, 6–12 April 2024, Page 1338
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial
Teluguakula Narasaraju a, Yazhini Ravi b, Colleen B Jonsson a, Vincent T K Chow c
doi : 10.1016/S0140-6736(23)02884-2
Volume 403, Issue 10434, 6–12 April 2024, Pages 1338-1339
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial
Sangeeta Bhusal a, Sudeep Adhikari b
doi : 10.1016/S0140-6736(23)02881-7
Volume 403, Issue 10434, 6–12 April 2024, Page 1339
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial – Authors' reply
Leon Peto a, Buddha Basnyat c, Peter Horby b
doi : 10.1016/S0140-6736(23)02879-9
Volume 403, Issue 10434, 6–12 April 2024, Pages 1339-1340
Department of Error
doi : 10.1016/S0140-6736(24)00646-9
Volume 403, Issue 10434, 6–12 April 2024, Page 1340
Department of Error
doi : 10.1016/S0140-6736(24)00650-0
Volume 403, Issue 10434, 6–12 April 2024, Page 1340
Department of Error
doi : 10.1016/S0140-6736(24)00647-0
Volume 403, Issue 10434, 6–12 April 2024, Page 1340
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Prof Domenica Lorusso MD PhD a, Prof Yang Xiang MD c, Prof Kosei Hasegawa MD PhD d, Prof Giovanni Scambia MD b, Prof Manuel Leiva MD e, Pier Ramos-Elias MD f, Alejandro Acevedo MD g, Prof Vladyslav Sukhin MD h, Noelle Cloven MD i, Andrea J Pereira de Santana Gomes MD j, Fernando Contreras MejÃa MD k, Ari Reiss MD l, Prof Ali Ayhan MD m, Jung-Yun Lee MD PhD n, Valeriya Saevets MD PhD o, Prof Flora Zagouri MD PhD p, Prof Lucy Gilbert MD q, Prof Jalid Sehouli MD PhD r s, Prof Ekkasit Tharavichitkul MD t, Prof Kristina Lindemann MD PhD u v…Prof Linda R Duska MD MPH ah *
doi : 10.1016/S0140-6736(24)00317-9
Volume 403, Issue 10434, 6–12 April 2024, Pages 1341-1350
Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial
Prof Jennifer L Steel PhD b e g, Charles J George MS k, Prof Lauren Terhorst PhD k, Jonathan G Yabes PhD a h n, Vincent Reyes MD o, Dan P Zandberg MD a, Marci Nilsen PhD l, Gauri Kiefer MD o, Prof Jonas Johnson MD c, Christopher Marsh MD o, Jason Bierenbaum MD o, Nishant Tageja MD o, Michal Krauze MD o, Robert VanderWeele MD o, Gaurav Goel MD o, Gopala Ramineni MD o, Prof Michael Antoni PhD p, Prof Yoram Vodovotz PhD b d f i j n, Jon Walker PhD m, Samer Tohme MD b…Prof David A Geller MD b
doi : 10.1016/S0140-6736(24)00015-1
Volume 403, Issue 10434, 6–12 April 2024, Pages 1351-1361
Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial
Chipepo Kankasa MD a *, Anaïs Mennecier PharmD b *, Beninwendé L D Sakana MD c, Jean-Pierre Molès PhD b, Mwiya Mwiya MD a, Catherine Chunda-Liyoka MD a, Morgana D'Ottavi MSc b, Souleymane Tassembedo MD c, Maria M Wilfred-Tonga MD a, Paulin Fao MD c, David Rutagwera MSc a, Beauty Matoka MSc a, Dramane Kania PharmD c, Ousmane A Taofiki MD c, Prof Thorkild Tylleskär MD d, Prof Philippe Van de Perre MD b †, Prof Nicolas Nagot MD b †, PROMISE-EPI Trial Group ‡
doi : 10.1016/S0140-6736(23)02464-9
Volume 403, Issue 10434, 6–12 April 2024, Pages 1362-1371
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials
Qingyang Shi MM a †, Yang Wang MB a †, Qiukui Hao MD b h, Prof Per Olav Vandvik MD i, Prof Gordon Guyatt MD h, Jing Li MD a, Zhe Chen MM j, Shishi Xu MD a, Yanjiao Shen MM a, Prof Long Ge MD k, Prof Feng Sun PhD l, Ling Li PhD a, Jiajie Yu PhD a, Kailei Nong MB a, Xinyu Zou MB a, Siyi Zhu MD c, Cong Wang MM d, Shengzhao Zhang BSc e, Zhi Qiao MS f, Zhongyu Jian MD g…Sheyu Li MD a
doi : 10.1016/S0140-6736(24)00351-9
Volume 403, Issue 10434, 6–12 April 2024, Pages e21-e31
Severe reactivation of seronegative occult hepatitis B after chemotherapy for lymphoma
Prof Harrys A Torres MD a b, Khalis Mustafayev MD a, Prof Loretta J Nastoupil MD c, Prof Samuel A Shelburne MD a
doi : 10.1016/S0140-6736(24)00397-0
Volume 403, Issue 10434, 6–12 April 2024, Pages 1372-1373
Under threat: the International AIDS Society–Lancet Commission on Health and Human Rights
Prof Chris Beyrer MD a b †, Prof Adeeba Kamarulzaman FRACP c †, Michael Isbell JD d, Prof Joseph Amon PhD e, Prof Stefan Baral MD b, Prof Mary T Bassett MD f, Javier Cepeda PhD b, Harriet Deacon PhD g, Lorraine Dean ScD b, Lilianne Fan MA h, Prof Rita Giacaman PharmD i, Carolyn Gomes MBBS j, Prof Sofia Gruskin JD k, Ravi Goyal PhD p, Sandra Hsu Hnin Mon MSPH l, Samer Jabbour MD m, Prof Michel Kazatchkine MD n, Kasoka Kasoka PhD d, Carrie Lyons PhD b, Allan Maleche LLM o…Prof Leonard Rubenstein JD b
doi : 10.1016/S0140-6736(24)00302-7
Volume 403, Issue 10434, 6–12 April 2024, Pages 1374-1418
